Video

Balancing Quality of Care and Costs in Urology Practices

Balancing costs while preserving access to high quality care is an important topic in cancer care. The recent explosion of new therapies for patients with urologic cancer has brought this issue to the forefront of conversation, particularly in advanced prostate cancer.

E. David Crawford, MD, and Mark S. Austenfeld, MD, believe this issue will continue to be discussed, as better medications and devices become available and costs continue to rise. Additionally, Crawford believes it may be best to combine these therapies, which would further increase the cost per treatment course. With multiple new drug approvals in the last few years extra costs are inevitable, Neal D. Shore, MD, notes. These extra costs are primarily tied to the high price of research and development for new drugs.

Ultimately, the panel agrees that physicians should remain conscious of costs while offering the best care to patients.

Related Videos
Janaki Neela Sharma, MD, University of Miami
Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.
Tiago Biachi, MD, PhD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Ami Umesh Badami, MD
Louis Crain Garrot, MD
Janaki Neela Sharma, MD
Alberto Montero, MD, MBA, CPHQ
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Thomas Westbrook, MD, assistant professor, Rush University Medical Center